ClinicalTrials.gg

Program

VIT-2763

Also written as “Vamifeport”, “Vamifeport (PR formulation)” and “Vamifeport IRF”.

Its studies are mostly in beta-Thalassemia · Hemochromatosis · Iron Overload · Anemia, Sickle Cell, led by CSL.

Furthest: phase 2, since Apr 1, 20207 company-led studies, 1 open or runningNext primary completion: Apr 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL71 open or runningphase 2since Apr 1, 2020Apr 1, 2020Apr 15, 2028phase 2 · NCT07332091

Also a collaborator on its studies: fortrea and labcorp-corporation-of-america-holdings-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 1, 2020First study: phase 2 study in beta-ThalassemiaFirst studyNCT04364269 · 35 enrolled · Greece, Israel, Italy and more
  2. Mar 23, 2021Phase 2 study in Anemia, Sickle CellNCT04817670 · 25 enrolled · United States, France, Greece and more
  3. Jun 16, 2021Phase 2 study in beta-ThalassemiaNCT04938635 · United States, Bulgaria, Israel
  4. Sep 20, 2021Phase 1 study in HealthyNCT05077436 · 28 enrolled · United Kingdom
  5. Dec 6, 2024Phase 1 study in Iron OverloadNCT06726863 · 22 enrolled · United Kingdom
  6. May 21, 2025Phase 1 study in Healthy VolunteersNCT06996184 · 28 enrolled · United Kingdom
  7. Jan 8, 2026Phase 2 study in HemochromatosisNCT07332091 · 84 enrolled · United States, Australia, Austria and more

Ahead

  1. Apr 15, 2028Primary completion: phase 2 study in HemochromatosisNCT07332091

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07332091Hemochromatosis · United States, Australia, Austria and more2Active, not recruitingApr 15, 202884
NCT06996184Healthy Volunteers · United Kingdom1CompletedJul 1, 202528
NCT06726863Iron Overload · United Kingdom1CompletedJan 27, 202522
NCT05077436Healthy · United Kingdom1CompletedDec 29, 202128
NCT04938635beta-Thalassemia · United States, Bulgaria, Israel2WithdrawnJul 20230
NCT04817670Anemia, Sickle Cell · United States, France, Greece and more2CompletedMar 7, 202425
NCT04364269beta-Thalassemia · Greece, Israel, Italy and more2CompletedOct 11, 202135

How it is read

Names in the registry

  • “Vamifeport”, 1 entry
  • “Vamifeport (PR formulation)”, 1 entry
  • “Vamifeport IRF”, 1 entry
  • “Vamifeport PR1”, 1 entry
  • “Vamifeport PR2”, 1 entry

Codes read as this program: CSL624.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.